Cardiovascular Disease, Executive Summary
We continue our Statesmen Series today and are honored to welcome Edwards Lifescience's CEO Mike Mussallem.
by Stephen Cervieri, Managing Director We continue our Statesmen Series today and are honored to welcome Edwards Lifescience's CEO Mike Mussallem.
Upcoming events
by Stephen Cervieri, Managing Director Upcoming events
A reminder that next week we will run the f
Last fall, the FDA got more power and funding to monitor drugs once they're on the market.
by Stephen Cervieri, Managing Director Clinical & Regulatory
Last fall, the FDA got more power
Regulatory: Orwell Meets the SEC
by Stephen Cervieri, Managing Director Regulatory: Orwell Meets the SEC
Shareholder democracy took a turn for the worse recently. The SEC has told public corporations that they would have to subsidize shareholder proposals urging the companies to take a lobbying
Leadership - Small Company Analysis
By Stephen Cervieri, Managing Director
Leadership - Small Company Analysis
Big-name cholesterol meds are losing ground on two fronts.
The Cardiology Lifeline is a tech-free zone (high-tech that is).
By Stephen Cervieri, Managing Director Mergers & Acquisitions
The Cardiology Lifeline is a tec
Regulatory - Update on Stent Guidelines
Regulatory - Update on Stent Guidelinesby Stephen Cervieri, Managing Director
A little dated, but we are cleaning out the news file.
No Good Deed Goes Unpunished
No Good Deed Goes Unpunishedby Stephen Cervieri, Managing Director
A leading AIDS med made by GlaxoSmithKline carries nearly double the risk of heart attack compared with other
Farsightedness – Next Generation Pharma Strategy
Farsightedness – Next Generation Pharma Strategyby Stephen Cervieri, Managing Director
FARSIGHTEDNESS is a trait often discussed, rarely put into action.
